Expertise in
17
conditions

Dr. Pashtoon M. Kasi

Oncology
City Of Hope
Irvine, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Expertise in
17
conditions
City Of Hope
Irvine, CA 

Overview

Pashtoon Kasi is an Oncologist practicing medicine in Irvine, California.

Dr. Kasi is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Familial Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 144 peer reviewed articles and participating in 18 clinical trials. Dr. Kasi is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in IA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

City Of Hope
Irvine, CA 92618

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: August 24, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
Enrollment Status: Recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Radiation
Study Phase: Phase 2
Alleviation by NIAGEN of Persistent Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors
Alleviation by NIAGEN of Persistent Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors
Enrollment Status: Active_not_recruiting
Publish Date: August 20, 2026
Intervention Type: Drug
Study Drug: Nicotinamide riboside
Study Phase: Phase 2
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2026
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors
First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors
Enrollment Status: Completed
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: ELI-002 Amph-CpG-7909
Study Phase: Phase 1
Immunotherapy Combined With Yttrium-90 RadioEmbolization in the Treatment of Colorectal Cancer With Liver Metastases [iRE-C - Clinical Trial]
Immunotherapy Combined With Yttrium-90 RadioEmbolization in the Treatment of Colorectal Cancer With Liver Metastases [iRE-C - Clinical Trial]
Enrollment Status: Terminated
Publish Date: March 28, 2025
Intervention Type: Radiation, Drug
Study Drug: Durvalumab
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

144 Total Publications

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.
Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.
Journal: Science advances
Published: June 26, 2026
Similar Doctors
Expertise in
33
conditions
Expertise in
33
conditions
Referral may be required

City Of Hope Orange County Lennar Foundation Cancer Center

Irvine, CA 
 (0.1 miles away)
844-975-4048
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tanya Siddiqi is an Oncologist practicing medicine in Irvine, California. Dr. Siddiqi is highly rated in 33 conditions, according to our data. Her clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Splenectomy.

Expertise in
29
conditions
Dr. Jaime Landman
Oncology | Urology
Expertise in
29
conditions
Dr. Jaime Landman
Oncology | Urology
Referral may be required

UCI Health Newport - Birch Street

20350 Southwest Birch Street, Suite 210, 
Newport Beach, CA 
 (8.5 miles away)
714-456-7005
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Dr. Jaime Landman, director of the UCI HealthCenter for Urological Care, is an internationally recognized urologist and expert in diseases and conditions of the kidneys, including kidney stones and benign and malignant tumors. He is experienced in all forms of minimally invasive kidney surgery, including robot-assisted surgery and percutaneous cryoablation.Landman, who founded the UCI HealthAblative Oncology Center,has performed thousands of advanced minimally invasive kidney procedures. He is dedicated to improving the techniques and technology associated with minimally invasive surgery.The author of more than 185 peer-reviewed articles and more than 60 book chapters, Landman has lectured around the world on the subject of minimally invasive urology. His research interests are in kidney cancer outcomes, kidney ablation and kidney imaging technologies, as well as preserving kidney function.His research efforts have helped define many of the minimally invasive kidney procedures performed today, earning him the 2005 Arthur Smith prize for creativity and dynamic innovation at the World Congress of Endourology. His clinical interests include all aspects of minimally invasive urologic oncology, with special emphasis on kidney cancer and kidney stone disease. Dr. Landman is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Kidney Stones, Renal Cell Carcinoma (RCC), Ureterocele, Lithotripsy, and Nephrectomy. Dr. Landman is board certified in American Board Of Urology - Urology.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

City Of Hope - Duarte Main Campus

1500 E Duarte Rd, 
Duarte, CA 
 (34.8 miles away)
626-256-4673
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alex Herrera is an Oncologist practicing medicine in Duarte, CA. He has been practicing medicine for over 17 years. Dr. Herrera is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Colonoscopy. Dr. Herrera is board certified in American Board Of Internal Medicine, Hematology and American Board Of Internal Medicine, Oncology.

Frequently Asked Questions about Dr. Pashtoon M. Kasi

How do I make an appointment with Dr. Pashtoon M. Kasi?

You can book an appointment with Dr. Pashtoon M. Kasi by calling their office at 888-201-2251. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Pashtoon M. Kasi a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Pashtoon M. Kasi is classified as an Elite expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Pashtoon M. Kasi specialize in?

While Dr. Pashtoon M. Kasi is a Oncology, they have specific expertise in Colorectal Cancer, Pancreatic Cancer, and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Pashtoon M. Kasi participate in research or clinical trials?

Yes. Dr. Pashtoon M. Kasi has published 144 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Pashtoon M. Kasi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Pashtoon M. Kasi accept my insurance?

Dr. Pashtoon M. Kasi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 888-201-2251 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kasi's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile